Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 14/20 | 0.53 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2647846 | 0.92 | GCK (0.54) | GCKPDE5AFFAR2MMEPOLB | |
| SCHEMBL2648518 | 0.90 | GCK (0.49) | GCKPDE5AFFAR2POLB | |
| SCHEMBL2648600 | 0.89 | GCK (0.47) | GCKPDE5AFFAR2 | |
| SCHEMBL2648681 | 0.86 | GCK (0.53) | GCKPDE5AMME | |
| SCHEMBL2646782 | 0.85 | GCK (0.70) | GCK | |
| SCHEMBL27467630 | 0.85 | GCK (0.49) | GCKPDE5AFFAR2 | |
| SCHEMBL2646189 | 0.84 | GCK (0.48) | GCKFFAR2 | |
| SCHEMBL2657931 | 0.84 | GCK (0.48) | GCKFFAR2 | |
| SCHEMBL2648107 | 0.84 | ALDH1A1 (0.56) | GCKPDE5APOLB | |
| SCHEMBL2647498 | 0.82 | GCK (0.50) | GCKPDE5AFFAR2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1282611-B1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-20 | — | — | EP | claimed |
| US-6384220-B2 | ANTIDIABETIC AGENTS INCREASING THE EXPRESSION OF GLUCOKINASE (GK) TO IMPROVE GLUCOSE TOLERANCE; INCREASE IN GLUCOSE EXPOSURE COUPLED THROUGH GK IN BETA-CELLS TO INCREASE INSULIN SECRETION AND IN HEPATOCYTES TO INCREASE GLYCOGEN DEPOSITION | HOFFMANN-LA ROCHE INC. | 2002-05-07 | — | — | US | claimed |
| US-20020002190-A1 | Para-aryl or heterocyclic substituted phenyl glucokinase activators | HOFFMANN-LA ROCHE INC. | 2002-01-03 | — | — | US | claimed |
| EP-1282611-B1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-20 | — | — | EP | disclosed |
| EP-1282611-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-12 | — | — | EP | disclosed |
| US-6384220-B2 | ANTIDIABETIC AGENTS INCREASING THE EXPRESSION OF GLUCOKINASE (GK) TO IMPROVE GLUCOSE TOLERANCE; INCREASE IN GLUCOSE EXPOSURE COUPLED THROUGH GK IN BETA-CELLS TO INCREASE INSULIN SECRETION AND IN HEPATOCYTES TO INCREASE GLYCOGEN DEPOSITION | HOFFMANN-LA ROCHE INC. | 2002-05-07 | — | — | US | disclosed |
| US-20020002190-A1 | Para-aryl or heterocyclic substituted phenyl glucokinase activators | HOFFMANN-LA ROCHE INC. | 2002-01-03 | — | — | US | disclosed |
| WO-2001085706-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002190-A1 | Para-aryl or heterocyclic substituted phenyl glucokinase activators | GCKR, GCK, PDXK | GCK 2/4885PDE5A 2050/4885FFAR2 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.